Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...

Strong R&D investment, advanced manufacturing technologies, and supportive government policies accelerate global API production growth.Austin, Texas, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Small Molecule ...

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

China and India, which are the largest producers of APIs for the U.S. drug supply, also account for most of the FDA regulatory actions. Not only do quality problems at Chinese and Indian firms raise ...

Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.

Bristol-Myers Squibb (BMS) has agreed to sell its small-molecule active pharmaceutical ingredient (API) manufacturing facility in Swords, Ireland, to Seoul, South Korea-based contract development and ...